The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to boost its domestic manufacturing and research ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Gilead will construct three new facilities in the U.S., while upgrading three others. The company claims the investment will ...

Shares of Gilead Sciences Inc. GILD rose 1.04% to $98.90 Wednesday, on what proved to be an all-around great trading session ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...